
    
      This Phase 2 study is to be conducted in two parts. Part A is a randomized, double-blind,
      placebo-controlled, parallel-group, dose-finding study of SC411 in children with SCD. This
      part of the study will consist of a screening period of up to 2 weeks, followed by an
      eight-week treatment period. Part B is an optional 49-month open-label extension for patients
      who have completed Part A.
    
  